Related Experiment Video

Updated: May 13, 2026

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

Molecular modeling of disease causing mutations in domain C1 of cMyBP-C

Poornima Gajendrarao1, Navaneethakrishnan Krishnamoorthy, Heba Sh Kassem

  • 1Qatar Cardiovascular Research Center, Qatar Foundation, Doha, Qatar.

Plos One
|March 26, 2013
PubMed

Insights

Mutations in cardiac myosin binding protein-C (cMyBP-C) domain C1 disrupt its structure and surface charge, impacting heart muscle contraction and potentially causing familial hypertrophic cardiomyopathy (HCM).

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Cardiac myosin binding protein-C (cMyBP-C) is crucial for regulating heart muscle contraction.
  • Mutations in cMyBP-C are a known cause of familial hypertrophic cardiomyopathy (HCM).
  • Domain C1 of cMyBP-C is vital for interactions with actin and myosin.

Purpose of the Study:

  • To investigate the structure-function relationship of three disease-associated mutations in cMyBP-C domain C1.
  • To understand how these mutations affect the structural integrity and protein interactions of domain C1.

Main Methods:

  • Computational biology techniques were employed.
  • The available X-ray crystal structure of cMyBP-C domain C1 was utilized.

Main Results:

  • Each mutation (Arg177His, Ala216Thr, Glu258Lys) uniquely alters the structural properties and integrity of domain C1.
  • Mutations modify intra-molecular arrangements within domain C1.
  • Surface charge distributions are altered, potentially affecting binding with sarcomeric proteins and contractile function.

Conclusions:

  • The studied mutations in cMyBP-C domain C1 lead to distinct structural changes.
  • These structural alterations can impact sarcomeric protein interactions and cardiac muscle function.
  • Understanding these molecular mechanisms is key to comprehending HCM pathogenesis.

More Related Videos

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...